Anti-DDIAS/ C11orf82/ noxin functional antibody

Anti-DDIAS/ C11orf82/ noxin functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to DDIAS/DDIAS products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-SE0583-Ab-1/ GM-Tg-hg-SE0583-Ab-2Anti-Human DDIAS monoclonal antibodyHuman
GM-Tg-rg-SE0583-Ab-1/ GM-Tg-rg-SE0583-Ab-2Anti-Rat DDIAS monoclonal antibodyRat
GM-Tg-mg-SE0583-Ab-1/ GM-Tg-mg-SE0583-Ab-2Anti-Mouse DDIAS monoclonal antibodyMouse
GM-Tg-cynog-SE0583-Ab-1/ GM-Tg-cynog-SE0583-Ab-2Anti-Cynomolgus/ Rhesus macaque DDIAS monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-SE0583-Ab-1/ GM-Tg-felg-SE0583-Ab-2Anti-Feline DDIAS monoclonal antibodyFeline
GM-Tg-cang-SE0583-Ab-1/ GM-Tg-cang-SE0583-Ab-2Anti-Canine DDIAS monoclonal antibodyCanine
GM-Tg-bovg-SE0583-Ab-1/ GM-Tg-bovg-SE0583-Ab-2Anti-Bovine DDIAS monoclonal antibodyBovine
GM-Tg-equg-SE0583-Ab-1/ GM-Tg-equg-SE0583-Ab-2Anti-Equine DDIAS monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-SE0583-Ab-1/ GM-Tg-hg-SE0583-Ab-2; GM-Tg-rg-SE0583-Ab-1/ GM-Tg-rg-SE0583-Ab-2;
GM-Tg-mg-SE0583-Ab-1/ GM-Tg-mg-SE0583-Ab-2; GM-Tg-cynog-SE0583-Ab-1/ GM-Tg-cynog-SE0583-Ab-2;
GM-Tg-felg-SE0583-Ab-1/ GM-Tg-felg-SE0583-Ab-2; GM-Tg-cang-SE0583-Ab-1/ GM-Tg-cang-SE0583-Ab-2;
GM-Tg-bovg-SE0583-Ab-1/ GM-Tg-bovg-SE0583-Ab-2; GM-Tg-equg-SE0583-Ab-1/ GM-Tg-equg-SE0583-Ab-2
Products NameAnti-DDIAS monoclonal antibody
Formatmab
Target NameDDIAS
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-DDIAS benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-SE0583-Ag-1Recombinant multi-species DDIAS/ C11orf82/ noxin protein


    Target information

    Target IDGM-SE0583
    Target NameDDIAS
    Gene ID220042,74041,499204,701440,485160,101100412,618360,100051077
    Gene Symbol and Synonyms4632434I11Rik,C11orf82,C21H11orf82,C29H11orf82,C7H11orf82,CD1H11orf82,DDIAS,noxin,RGD1559690
    Uniprot AccessionQ8IXT1
    Uniprot Entry NameDDIAS_HUMAN
    Protein Sub-locationSecreted Protein/Potential Cytokines
    Category
    DiseaseN/A
    Gene EnsemblENSG00000165490
    Target ClassificationN/A

    The target: DDIAS, gene name: DDIAS, also named as C11orf82, noxin. Involved in negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage and regulation of DNA stability. Predicted to be active in cytoplasm and nucleus. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.